Home Business & Finance Lilly’s revenue soars 48%, driven by demand of its GLP-1s
Business & Finance

Lilly’s revenue soars 48%, driven by demand of its GLP-1s

Lilly’s revenue soars 48%, driven by demand of its GLP-1s
Key Points

Its sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.

Its sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.
Lilly (ORG) Mounjaro (ORG) Zepbound (PERSON)
Originally published by MarketWatch Read original →